What we know about Parkinson’s in the UK

Parkinson’s UK has produced the most comprehensive picture yet of how Parkinson’s affects people across the country. Drawing on more than 18 million patient records from GP surgeries, hospital admissions and prescription data — around a quarter of the UK population — the charity has built an evidence base that is both sobering and necessary. The findings show that more people than ever are living with Parkinson’s, that many remain undiagnosed, and that who gets diagnosed still depends far too much on where you live and who you are. The current estimate is that around 166,000 people in the UK have been diagnosed with Parkinson’s, up from the previous figure of 153,000. This rise largely reflects an ageing population rather than a sudden surge in new cases. By 2030, the number is expected to reach roughly 174,000. Before the COVID-19 pandemic, more than 26,000 people were diagnosed every year. During the pandemic, however, diagnosis rates fell sharply to around 19,000 a year. That drop did not mean fewer people developed the condition; it meant fewer were seen, investigated or referred to specialists at the right time. The study also found that up to 21,000 people in the UK may be living with Parkinson’s but have not yet been diagnosed. Alongside them, roughly 28,000 people have other forms of Parkinsonism such as progressive supranuclear palsy or multiple system atrophy. These conditions share some symptoms but differ in cause and treatment. The data reveal clear demographic patterns. Men are more likely to be diagnosed than women. People in urban or more deprived areas are less likely to receive a diagnosis, as are those from minority ethnic backgrounds, including Black, Chinese, White Irish and mixed ethnic groups. Regional variation was also seen, with people in Scotland being diagnosed less often than those in other parts of the UK. Such differences point to inequalities in awareness, access to care, and possibly differences in how symptoms are recognised or reported. Life expectancy remains shorter on average for people with Parkinson’s than for the general population, though the degree varies widely. The disease progresses very differently from person to person. Some live for decades with manageable symptoms, while others experience faster decline. For that reason, many people value having clear information for planning their futures, while others prefer not to focus on average survival figures that may not apply to them. This large-scale analysis carries major implications. More people with Parkinson’s means more demand for neurologists, Parkinson’s nurses, physiotherapists, speech therapists, occupational support, and ongoing research funding. The drop in diagnoses during the pandemic shows how easily access to care can be disrupted. The existence of thousands of undiagnosed people, and the stark differences across regions and communities, underline that Parkinson’s is not only a medical issue but also a social one. Better data like this helps shape policy, guide investment and ensure future services match the scale of the challenge. Increasingly, digital tools like PD Buddy are helping people with Parkinson’s manage their condition while also easing the pressure on an overstretched NHS. They provide accessible therapies, up-to-date information, and even AI-generated guidance that, while not a replacement for professional care, can be checked and validated with a doctor. By giving users a way to track symptoms, follow routines, and access personalised insights between appointments, these platforms help people stay on top of their health, reduce unnecessary clinic visits, and support healthcare teams in focusing their attention where it is most needed. While such tools are not a solution to the broader structural challenges in diagnosis or treatment, they are increasingly an essential part of living well with Parkinson’s in today’s healthcare environment.